Cardiovascular Adverse Events (CVAE) Associated With Second Generation Bruton Tyrosine Kinase (BTK) Inhibitor (BTKi) Therapy in Patients With Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Meta-Analysis

被引：0
|
作者：
Proskuriakova, Ekaterina [1 ]
Shrestha, Dhan [1 ]
Jasaraj, Ranjit [1 ]
Mercado, Gustavo Espinoza [1 ]
Wortstman, Josh [1 ]
Kovalenko, Iulia [2 ]
Khosla, Pam [1 ]
机构：
[1] Mt Sinai Hosp, Chicago, IL USA
[2] UPMC, Harrisburg, PA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
CLL; Bruton tyrosine kinase inhibitor; acalabrutinib; zanubrutinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CLL-428
引用
收藏
页码：S327 / S328
页数：2
相关论文
共 50 条
  • [21] CHLORAMBUCIL FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - SYSTEMATIC REVIEW AND META-ANALYSIS
    Vidal, L.
    Gurion, R.
    Gafter-Gvili, A.
    Raanani, P.
    Bairy, O.
    Robak, T.
    Shpilberg, O.
    HAEMATOLOGICA, 2012, 97 : 57 - 57
  • [22] ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients
    Covey, Todd
    Barf, Tjeerd
    Gulrajani, Michael
    Krantz, Fanny
    van Lith, Bart
    Bibikova, Elena
    van de Kar, Bas
    de Zwart, Edwin
    Hamdy, Ahmed
    Izumi, Raquel
    Kaptein, Allard
    CANCER RESEARCH, 2015, 75
  • [23] Real-World Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Patterns Among Patients with Chronic or Small Lymphocytic Leukemia (CLL/SLL) in US Community Oncology Practices
    Hou, Jing-Zhou
    Blanc, Simon
    Maglinte, Gregory A.
    Vasudevan, Anupama
    Rui, Anna
    Gart, Michael
    Hoa Pham
    Aton, Lindsay
    Wang, Brandon
    Choksi, Rushir
    BLOOD, 2023, 142
  • [24] COST-MINIMIZATION ANALYSIS (CMA) OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN ADULTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Chanan-Khan, A.
    Mohseninejad, L.
    Walder, L.
    Ubi, S.
    Gani, R.
    Shah, A.
    Yang, K.
    VALUE IN HEALTH, 2023, 26 (12) : S182 - S182
  • [25] Systematic literature review (SLR) of treatments and outcomes in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with Bruton tyrosine kinase inhibitors (BTKi) and venetoclax
    Wang, Lin
    Hartley, Louise
    Hawe, Emma
    Kangappaden, Teresa
    Laidlaw, Alyshia
    Sharman, Jeff
    LEUKEMIA & LYMPHOMA, 2023, 64 : S54 - S55
  • [26] COMPARATIVE BAYESIAN NETWORK META-ANALYSIS OF BTKI-SPECIFIC ADVERSE EVENTS IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Monica, M.
    Reczek, M.
    Kawalec, P.
    VALUE IN HEALTH, 2024, 27 (06) : S29 - S30
  • [27] Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia A systematic review and meta-analysis of randomized trials
    Zhou, Yanhua
    Lu, Hongtao
    Yang, Meifeng
    Xu, Chenhong
    MEDICINE, 2019, 98 (33)
  • [28] Cardiovascular events in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors: A systematic review and meta-analysis.
    Chai-Adisaksopha, Chatree
    Hillis, Christopher Michael
    Lam, Wilson
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Real-world Bruton tyrosine kinase inhibitor (BTKi) treatment patterns and outcomes among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) in US community oncology practices
    Hou, Jing-Zhou
    Blanc, Simon
    Maglinte, Gregory A.
    Vasudevan, Anupama
    Rui, Anna
    Gart, Mike
    Pham, Hoa
    Aton, Lindsay
    Wang, Brandon
    Choksi, Rushir J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Reversible posterior leukoencephalopathy syndrome (RPLS) in a patient with chronic lymphocytic leukemia (CLL) treated with Acalabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor: a case report
    Janssens, L.
    Huybrecht, S.
    De Blauwe, S.
    Vanopdenbosch, L.
    Parmentier, H.
    ACTA NEUROLOGICA BELGICA, 2024, : 553 - 555
12345